VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast

Jul 28, 2015, 08:00 ET from VirtualScopics, Inc.

ROCHESTER, N.Y., July 28, 2015 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, today announced that it will report its second quarter 2015 financial results at the 4:00 p.m. ET market close on Tuesday, August 11, 2015.  Eric T. Converse, president and chief executive officer, and Jim Groff, chief financial officer, will host a conference call and webcast to discuss the company's financial results and provide a business update at 4:30 p.m. ET that afternoon.  Conference call, webcast and replay information is as follows:

            Domestic Call Dial In:  877-407-8035             International Call Dial In:  201-689-8035             Conference Call ID:  13615639 An accompanying slide presentation to enhance managements' formal remarks, as well as a webcast of the call, can be accessed at: http://virtualscopics.investorroom.com/webcasts or at:  http://www.investorcalendar.com/IC/CEPage.asp?ID=174218

A replay and slide presentation will be available one hour after the conclusion of the conference call for 90 days, and can be accessed accordingly:

            Replay Domestic Dial In:  877-660-6853             Replay International Dial In:  201-612-7415             Replay Conference Call ID:  13615639             Webcast and slide presentation can be accessed at:  http://virtualscopics.investorroom.com/webcasts or at: http://www.investorcalendar.com/IC/CEPage.asp?ID=174218

About VirtualScopics, Inc. VirtualScopics, Inc. (NASDAQ: VSCP) is a leading provider of clinical trial imaging solutions to accelerate drug and medical device development.  For risk-averse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics' clinical trial imaging solutions are an inspired true exception to commonly accepted services provided by other clinical trial imaging providers.  Because of the scientific and operational flexibility and responsiveness available, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, every day clinical trial imaging services.  For more information about VirtualScopics, Inc., please visit www.virtualscopics.com.

Forward-looking Statements The statements contained in this press release that are not purely historical are forward-looking Statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby.  These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure, new office in New Hope, Pennsylvania, the Scientific Advisory Board, the strategic alliance with IXICO plc, the increase in awards outstanding and bookings and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions.  Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations.  Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov.  These include without limitation:  the risk of cancellation or delay of customer contracts or specifically as it relates to contract awards, the risk that they may not get signed.  Other risks include the Company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others.  All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

For More Information, Contact: Donna N. Stein, APR, Fellow PRSA Managing Partner Donna Stein & Partners 315-361-4672 Email:  dstein1@twcny.rr.com 

SOURCE VirtualScopics, Inc.



RELATED LINKS

http://www.virtualscopics.com